Fumay

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fumay

Property Description
Active ingredient Fluconazole
Form Tablets, Oral Suspension, Sterile Solution
Pharmacological class Triazole Antifungal
Common use Systemic Fungal and Yeast Infections
Origin Synthetic Compound

What Type of Medicine is Fumay (Fluconazole)?

Fumay is a pharmaceutical medication specifically classified as a Triazole Antifungal agent, utilized to manage infections caused by fungi and yeasts. Its core composition features the active substance Fluconazole, a powerful, synthetic molecule designed to work systematically throughout the body. The drug is clinically recognized for its efficacy against common fungal pathogens across various body sites.

This agent is a single-ingredient product focused entirely on the action of Fluconazole, placing it within the broader azole class of antifungals. Fluconazole's high oral bioavailability ensures the medication is efficiently distributed to reach the infection site.


Fumay’s Physical Forms and Administration Routes

Fumay is manufactured in diverse pharmaceutical preparations to ensure flexibility in treatment, most commonly including solid tablets for swallowing and a sterile solution for infusion. The medication is officially available for both Oral (by mouth) and Intravenous (via injection or infusion) routes of administration, a key factor in managing patients who may not be able to tolerate oral intake.

The availability of both oral forms (tablets and a powder for oral suspension) and the intravenous solution ensures the drug can be administered effectively in various clinical settings. These versatile preparations are utilized for managing systemic fungal infections.


The General Purpose of This Antifungal Agent

The general purpose of Fumay is to counteract the progression of systemic fungal diseases by directly interfering with the survival structure of the pathogen. It works by halting the growth of fungi, effectively establishing a fungistatic action against the invading organisms.

This crucial mechanism involves blocking the fungus from producing ergosterol, a necessary building block for its outer cell membrane. By compromising the fungal cell's structural integrity, the medication prevents the infection from spreading. This action is central to its role as a systemic defense against various fungal pathogens, such as treating infections that spread through the bloodstream.

What side effects are possible with Fumay?

Possible Side Effects and Safety Information

The official regulatory safety profile for Fumay, which contains Fluconazole, is defined by a structured classification of adverse reactions based on their frequency and the physiological system affected. These classifications ensure transparency regarding the medicine's established risks, as detailed in government-approved prescribing information.


Documented Adverse Reaction Frequency

Adverse events are categorized into frequency bands consistent with regulatory standards. Common reactions documented in official sources include headache, abdominal pain, diarrhea, nausea, vomiting, and increases in liver enzymes (aminotransferases). Uncommon events may involve dizziness, fatigue, and taste perversion. Rare reactions include severe, clinically significant events.


Serious Safety Considerations

The official labels specifically warn of certain Serious Adverse Reactions (SARs). These include severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, and potentially fatal hepatotoxicity (liver injury). Rare but documented effects on the heart's electrical activity, such as QT prolongation and Torsade de pointes, are also noted. Regarding liver effects, regulatory documents state that severe reactions have occurred in patients with underlying medical conditions and are not consistently related to the dose or duration of therapy.


Population and Safety Limitations

Safety statements require caution for patients with existing hepatic impairment and renal impairment. The medicine is contraindicated in individuals with known hypersensitivity to fluconazole or other azole derivatives. Further limitations exist for patients with pre-existing risk factors for QTc prolongation.

Overdose and Emergency Response

In the event of a suspected overdose of Fumay (Sulfamethoxazole and Trimethoprim), government regulatory documents mandate seeking emergency medical attention immediately and contacting a poison control resource. This guidance applies upon the manifestation of any acute symptoms or severe outcomes.

Documented Overdose Manifestations

Acute overdose exposure is officially associated with specific gastrointestinal and Central Nervous System (CNS) effects. Documented acute presentations include loss of appetite, vomiting, nausea, and colic. CNS manifestations described in official labeling include confusion, dizziness, headache, and drowsiness. Fever (pyrexia) is also listed as a potential systemic effect.

Severe Outcomes and Required Management

Overdose may lead to severe and late manifestations, which are documented to include blood dyscrasias and jaundice (yellowing of the skin or eyes). Potential urinary complications, such as hematuria (blood in the urine) and crystalluria, may also occur. The official treatment strategy is strictly symptomatic and supportive, as no specific antidote is known for this overdose. Monitoring requirements are critical, mandating patient laboratory work to check for evidence of these severe outcomes, specifically blood dyscrasias or electrolyte imbalances. Patients with severely impaired renal function and infants younger than 2 months of age are documented to be at increased risk of toxicity following overdose.

Therapeutic Uses of Fumay

What Fumay Treats: Main Uses and Benefits

Fumay (known generically as co-trimoxazole, a combination of sulfamethoxazole and trimethoprim) is commonly used to help with bacterial infections that cause symptomatic discomfort across various body systems. This combination may be applied in contexts where additional symptomatic support is needed in conditions like urinary and respiratory issues, and other sites of symptomatic infection.


Symptom Relief and Stability Support

This medication helps address symptoms related to inflammatory or irritative states caused by susceptible bacteria, such as fever, localized pain, and swelling. It is generally applied in conditions that present with systemic or localized discomfort. It is relevant when supportive symptom management is appropriate and symptoms create noticeable physiological strain.

In the context of the illness, Fumay provides support that helps ease the overall symptom burden and supports the patient during difficult episodes by easing distress. It is applied during phases when symptoms become more noticeable and short-term symptomatic assistance is needed, and may assist with maintaining functional stability.

“It is commonly used across conditions presenting with acute episodes and offers symptomatic relief that may assist patients in coping more steadily.”


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fumay — Official Regulatory Information

This section outlines the populations defined as eligible or ineligible for Fumay based strictly on contraindications and special warnings documented in official governmental regulatory sources (e.g., FDA, EMA).


Regulatory Eligibility Scope

Classification Official Regulatory Constraint
Populations Contraindicated Patients with a known history of serious hypersensitivity or allergy to Fumay or to any component (excipient) of its formulation must not use this medicine.
Populations Not Recommended Use is generally not recommended in the presence of an active systemic infection; treatment should be delayed until the infection resolves.
Age-Related Rules Eligibility is restricted by minimum age and/or weight requirements as formally established in the regulatory documentation for pediatric use. Safety and effectiveness are typically not established for infants below the minimum specified age (e.g., 3 months).
Condition-Specific Rules Use may require special consideration or dosage adjustment in patients with hepatic impairment or renal impairment, as the drug is cleared by these organs. Specific viral serostatus markers (e.g., Hepatitis B/C, HIV) may mandate exclusion if officially deemed risk factors.
Pregnancy/Lactation Status Use during pregnancy and lactation is permitted only if explicitly labeled as safe or when the treating clinician has determined it is necessary, according to the formal eligibility status defined in the regulatory documentation.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Fumay by establishing absolute contraindications, which immediately exclude individuals with a prior serious allergic history to the drug. Eligibility is further constrained by rules regarding age/weight and clinical state, requiring that the patient meet specific requirements and not have an active infection. This structure ensures that individuals receiving the medicine are within the population for whom the drug's safety and effectiveness have been formally established and approved.

What should I know about interactions with other medicines?

The interaction profile of Fumay is defined by several regulatory restrictions and pharmacokinetic patterns. Formal Prohibitions are established for co-administration with multiple medicinal products due to the documented risk of severe cardiotoxicity, including Astemizole, Cisapride, Pimozide, Quinidine, and Erythromycin. Co-administration with Terfenadine is also contraindicated when Fumay doses are 400 mg per day or higher.

The primary basis for numerous interactions is Fumay’s official classification as a potent inhibitor of CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4 enzymes. This metabolic alteration can significantly increase the exposure of co-administered drugs, such as the anti-inflammatory agent Celecoxib, whose exposure is documented to increase by over 130%. Conversely, Rifampicin co-administration results in a 25% decrease in Fumay’s own plasma exposure, while Hydrochlorothiazide increases Fumay plasma concentrations by 40%.

Beyond metabolic effects, Pharmacodynamic Risks are documented, such as the increased risk of bleeding events when Fumay is combined with anticoagulants like Warfarin. Co-administration with HMG-CoA Reductase Inhibitors (Statins) carries an increased regulatory-documented risk of myopathy and rhabdomyolysis. Fumay’s absorption is officially unaffected by food or antacids. Furthermore, specific population notes indicate that renal impairment markedly affects Fumay’s elimination and half-life, a factor influencing interaction severity.

Mechanism of Action

Fumay (Fluconazole) operates by a specific interaction focused on the fungal pathogen's internal biochemical machinery.


Inhibition of Fungal CYP51 Enzyme

The mechanism begins with a specific interaction where the molecule acts as an inhibitor of the fungal enzyme Cytochrome P450 14-alpha-lanosterol demethylase (CYP51) . This enzyme is crucial for fungal cell function. By forming a tight coordinate bond with the enzyme’s heme iron, Fluconazole modifies an early molecular step that influences the structural integrity of the pathogen. This action restricts the fungal cell's sterol synthesis, impacting its structural components.


Disruption of the Ergosterol Biosynthesis Cascade

The blockage of CYP51 initiates a cascade that fundamentally alters the fungal cell membrane. The pathway effect is twofold: it restricts the production of ergosterol, the key structural sterol, and simultaneously causes the accumulation of toxic, functionally abnormal 14-alpha-methyl sterols. This physiological adjustment compromises the cell's integrity and leads to a fungistatic effect, which is the mechanism by which the growth of the organism is constrained.

Dosage and Administration Information

Fumay (fluconazole) is administered through two officially approved routes: Oral administration, utilizing tablets or the liquid suspension, and Intravenous (IV) administration, delivered via infusion in clinical settings. The availability of both forms allows for consistent treatment across different care environments.

The official dosing protocol typically begins with a loading dose on the first day, often double the amount of the maintenance dose, a strategy utilized to achieve effective systemic concentrations rapidly. This is followed by a maintenance dose, which can range from 100 mg to 400 mg once daily, or 150 mg once weekly, depending on the specific application. The medication may be taken without regard to meals, allowing for flexibility in daily timing.

The duration of administration is highly variable, ranging from a single oral dose for acute conditions to regimens extending long-term (months or indefinitely) for suppressive therapy. Procedural instructions require that the powder for oral suspension be shaken well before each use. Furthermore, the intravenous solution must be administered slowly, at a rate officially constrained to not exceed 10 mL per minute.

A critical component of the labeled instruction concerns population-specific adjustments. For individuals with significant renal impairment (Creatinine Clearance ≤ 50 mL/min), the required maintenance dose is officially reduced by 50% following the initial loading dose.

Recent Clinical Evidence

Fumay: Recent Clinical Evidence

Fumay (Cefuroxime) is a second-generation cephalosporin antibiotic used to address a range of bacterial infections. Recent research and clinical practice focus on defining its role in managing common infections, optimizing dosing, and assessing its safety profile across different patient groups, including children.


Primary Indications and Effectiveness

Studies consistently support the use of Fumay for bacterial infections in the respiratory tract (including pneumonia and pharyngitis), urinary tract, skin and soft tissues, as well as in bones and joints. It is frequently employed in hospitals and clinical settings, often in an injectable formulation, and is also used as a preventative measure before certain surgical procedures.

Clinical trials and evidence summaries indicate that symptom improvement often begins within 48 to 72 hours after starting the medication, though patients are consistently advised to complete the full course as prescribed to ensure infection clearance and prevent the development of antibiotic resistance.


Key Research Areas and Patient Populations

Research Focus Study Details
Pediatric Use Studies have established the use of Fumay in children aged 3 months and older for treating various bacterial infections. Safety and effectiveness are not yet established for infants under 3 months.
Safety in Pregnancy/Breastfeeding Clinical evidence, supported by animal studies, suggests that the drug is generally considered safe for use during pregnancy when prescribed. Human studies indicate minimal passage into breastmilk, suggesting it is safe for breastfeeding when used appropriately.
Kidney/Liver Function Limited information suggests caution and potential dose adjustments may be necessary for patients with pre-existing kidney disease. The drug is generally considered safe for use in patients with liver disease, though consultation is recommended for severe cases.

Key Studies & References

  1. CEFUROXIME AXETIL tablet: FDA-Approved Labeling and Patient Information
  2. Cefuroxime: Clinical Indications, Mechanism, and Therapeutic Use – StatPearls
  3. Cefuroxime and Breastfeeding: Drug Levels and Effects in Infants – Drugs and Lactation Database (LactMed®)
  4. Prospective Cohort Study Investigating the Safety and Efficacy of Ambulatory Treatment With Oral Cefuroxime-Axetil in Febrile Children With Urinary Tract Infection

Frequently Asked Questions (FAQ)

Common questions about Fumay (FAQ)

Q: What general statements are made about stopping the use of Fumay?

Official information describes that discontinuing Fumay should be done only under the direction of a healthcare professional. The completion of the full prescribed course is often described as necessary to effectively address the condition.

Q: How does the body eliminate Fumay after it is taken?

Fumay is primarily eliminated from the body by the kidneys. Official product information indicates that approximately 80% of the dose is passed out in the urine as the unchanged drug.

Q: What is the typical duration that Fumay remains active in the system?

According to regulatory pharmacokinetics data, the drug has a plasma half-life of approximately 30 hours. Due to this longer duration, the drug’s effects on metabolic enzymes may persist for several days after the final dose is taken.

Q: What is the significance of the specific warnings on the Fumay Patient Information Leaflet?

Official warnings in patient leaflets document the potential for rare but serious adverse reactions. These can include severe skin disorders, serious liver injury, and specific changes to heart rhythm (QT prolongation). These warnings are documented to describe the known risks associated with the medicine, based on regulatory evaluation.

Q: What happens in the body when Fumay is metabolized?

Fumay is described as metabolically stable, meaning the body breaks down only a small amount of the drug itself. It is primarily significant for its effect on other drugs, as it is known to inhibit certain CYP enzymes (like CYP2C9 and CYP2C19), which are crucial for metabolizing many other medicines.

Q: Does taking Fumay at a specific time of day matter, based on official instructions?

Official guidance states that Fumay can be taken without regard to meals, offering flexibility. However, official instructions often recommend consistent timing, such as taking the medication at the same time each day, to help ensure stable drug levels in the body.

Q: Are there any reports about Fumay affecting mental clarity or focus?

Regulatory adverse event listings indicate that side effects such as dizziness and fatigue are uncommon. This risk is why patient guidance includes a caution regarding activities like driving or operating machinery until it is known how the medication affects the individual.

Q: Are there any common supplements or vitamins that interact with Fumay?

Regulatory guidance specifically states that there is not enough official information to confirm the safety of taking herbal remedies, supplements, or complementary medicines with Fumay. Due to the potential for interactions, a discussion with a healthcare provider before combining supplements is generally relevant.

Q: Does Fumay have a generic version available, according to regulatory bodies?

Yes, official drug information confirms that the drug is available in a generic formulation, in addition to any brand-name versions.

Q: Are there any official warnings or precautions about using Fumay for older adults?

Official guidance notes that older adults are more likely to have naturally reduced kidney function. For this population, official guidance indicates that a dose adjustment may be necessary, often determined by calculated creatinine clearance.

Q: Can Fumay be taken with common over-the-counter pain medications?

Fumay is known to inhibit certain metabolic enzymes, meaning it can potentially affect the concentration of many co-administered medicines, including common pain relievers. Given this potential metabolic interaction, consulting with a healthcare professional regarding co-administered medications is important.

Q: Does consuming alcohol while using Fumay have any documented interactions?

Direct, documented interactions between Fumay and alcohol are not generally reported in official documentation. However, because both substances involve liver processing, a general note of caution may be relevant.

Q: Does Fumay affect a person's ability to operate machinery or drive?

Due to the possibility of experiencing side effects like dizziness or drowsiness, patient guidance advises caution regarding driving or operating complex machinery. This precaution exists until the individual can assess the effects of the medication on their coordination and focus.

Q: What should a patient generally know about a missed dose of Fumay?

Official instructions describe the protocol: if a dose is missed, it is typically taken as soon as it is remembered, unless the next dose is almost due. Patients are explicitly advised not to take a double dose to make up for the missed one.

Q: Does Fumay have any known effect on a person's weight or appetite?

Loss of appetite (clinically termed anorexia) is listed in official adverse event documents as an uncommon effect of Fumay.

Q: What high-level evidence exists on the long-term safety of Fumay?

Regulatory bodies have issued safety communications related to the long-term, chronic, high-dose use of Fumay in specific patient populations. This indicates that potential long-term risks have been monitored and documented, leading to specific guidance for prescribers and patients.

How should Fumay be stored and disposed of?

How to Store and Dispose of Fumay (Co-trimoxazole)

Fumay must be stored according to the official regulatory requirements to ensure product stability. The tablets and oral suspension require storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must not be refrigerated or frozen, as mandated by the labeling.

Item Official Requirement
Container Rule Keep the container tightly closed when not in use.
Suspension Stability The prepared oral suspension must be discarded after 14 days from mixing.
Child Safety Store the product out of the reach of children.

Unused or expired Fumay must be disposed of in accordance with local regulations. Follow guidelines for proper pharmaceutical waste handling, which typically involves collection programs or specific household disposal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fumay found in:

A-Z Index: